Press release
bitop AG and Alfa Intes signed License and Supply Agreement for Ectoin® Allergy Eye Drops 2%
“Alfa Intes is an experienced and well established partner for the Italian ophtalmics market” said Daniel J. Berger, CFO of bitop AG. “We are confident that from this collaboration all parties will profit: Alfa Intes, bitop AG and, needless to say, sufferers of allergic conjunctivitis.”
Allergic conjunctivitis is one of the most prominent forms of seasonal allergies such as hay fever. Standard treatment is performed with pharmaceutical eye drops containing corticosteroids, antihistamines or cromoglicic acid. The Ectoin® Allergy Eye Drops 2% fill a gap in the market for the treatment of allergic conjunctivitis because they combine natural effectiveness with high tolerability.
Ectoin® is a natural compound firstly found in a desert. There it protects microorganisms from hostile conditions. Used in humans, it has inflammation-reducing, cell-protective and regeneration supporting properties. Due to its excellent safety profile, it can be used in products for young, elderly, and sensitive persons
bitop AG, a German company founded in 1993, is focused on the development of Ectoin®-containing medical devices. Besides its Ectoin Allergy Eye Drops it is offering nasal sprays for the symptomatic treatment of acute rhinosinusitis and rhinitis sicca, eye drops for the treatment of symptoms in case of dry eye syndrome or creams which alleviate symptoms in case of inflammatory skin diseases. bitop AG is worldwide the only manufacturer of Ectoin®.
Alfa Intes Terapeutica Splendore Srl is a private pharmaceutical company located in Casoria (Na), Italy, focused on ophthalmics and also dealing with the production and control of proprietary medicine for national and international markets. Alfa Intes mission is to provide products and services for the prevention and treatment of eye diseases according to national and international standards of quality and safety.
Dr. Silke Behne
bitop AG, Stockumer Strasse 28, 58453 Witten, Germany
Phone: +492302914400
Internet: www.bitop.de
E-Mail: info@bitop.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release bitop AG and Alfa Intes signed License and Supply Agreement for Ectoin® Allergy Eye Drops 2% here
News-ID: 260463 • Views: …
More Releases from bitop AG
bitop is exhibitor at the in-cosmetics
At this year’s in-cosmetics show, taking place on April 1-3 in Hamburg, Germany, the cosmetics department of the extremolyte specialist bitop will showcase for the first time its product portfolio at booth 1K50.
Focus of the exhibition at the in-cosmetics is the presentation of bitop’s broad extremolyte product portfolio – including the well-known Ectoin® - but also of new ingredients with innovative properties.
Innovative ingredients that fulfil customer…
bitop strengthens its sales activities for the Personal Care Industry
bitop today announced that it has recently gained DKSH International Ltd. and C.H. Erbslöh KG Chemiehandel as distribution partners to strengthen its business with cosmetic active ingredients. By means of these cooperations, bitop can offer its new active cosmetic ingredients Glycoin® natural and 28Extremoin® to manufacturers of the personal care industry in Asia and the most important European countries. Furthermore bitop is able to strengthen its business with its established…
bitop AG receives Frost & Sullivan’s 2013 New Product Innovation Award for its …
The Ectoin® Allergy product line is expected to revolutionize the way allergies are treated.
Witten - June 18th 2013 – Frost & Sullivan, a global research organization of 1,800 analysts and consultants, monitors more than 300 industries and 250,000 companies to determine how best-in-class companies worldwide manage growth, innovation and leadership. Based on the findings of this research, Frost & Sullivan grants the 2013 European New Product Innovation Award in Extremolytes…
bitop AG and JGL d.d. Croatia signed License and Supply Agreement for Ectoin® A …
bitop AG today announced that it has recently entered into an exclusive license and supply agreement with JADRAN-GALENSKI LABORATORIJ d.d. (JGL d.d.) for bitop’s Ectoin® Allergy Nasal Spray 2%. Under this agreement, JGL d.d. will have the right to sell the nasal spray under its Aqua Maris® brand in various countries of the CEE and CIS regions. The agreement is valid for 3 years. The sale of the product with…
More Releases for Alfa
Biological Treatment Technologies Market May Set Epic Growth Story | Alfa-Therm, …
Pro Market Reports published a new research publication on "Biological Treatment Technologies Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Biological Treatment Technologies market was mainly driven by the increasing R&D spending across the world.
Some of the key players…
New Pump Handbook from Alfa Laval
Alfa Laval just published a brand new edition of the company's renowned Pump Handbook. The 375-page handbook is free and contains scholarly information on basic pump functionality and in-depth guidelines for sizing and selecting the right pump type for optimum efficiency. The handbook is packed with real-life examples to increase its user-friendliness.
The first edition of the Alfa Laval Pump Handbook was published 25 years ago and soon became part of…
Salicylic Acid Market Growth Potential is Booming Now: Alfa Chemistry, Novacap G …
HTF Market Intelligence recently released a survey document on the Salicylic Acid market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision-makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, and emerging trends along with essential drivers, challenges, opportunities, and restraints in…
Hybrid Heat Exchanger Market 2020 Strategic Assessment - Alfa Laval AB(STO: ALFA …
"Global Hybrid Heat Exchanger Market Report 2020-2026" helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market - driven results deriving feasibility studies for client needs. Marketinsightsreports ensures qualified and verifiable aspects of market data operating in the real- time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in…
Alfa Chemistry Launched Microalgae Powder Services
On October 24, 2019, Alfa Chemistry announced that it has launched microalgae powder production services.
Alfa Chemistry is a high-tech company specializing in the cultivation of microalgae powder and the production of related natural extracts. It has obtained more than 75 patents in the breeding, cultivation, processing and extraction of microalgae, serving customers in the feed, food, nutraceutical and pharmaceutical sectors. At present, the annual production capacity of Alfa Chemistry's microalgae…
Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80% of Global Erythropoie …
Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). This erythropoietin (EPO) drugs are used for the treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to the development of synthetic forms of erythropoietin such as epoetin…
